Torii Pharmaceutical Co Ltd
TSE:4551

Watchlist Manager
Torii Pharmaceutical Co Ltd Logo
Torii Pharmaceutical Co Ltd
TSE:4551
Watchlist
Price: 4 435 JPY 0.68% Market Closed
Market Cap: 127.7B JPY
Have any thoughts about
Torii Pharmaceutical Co Ltd?
Write Note

Torii Pharmaceutical Co Ltd
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Torii Pharmaceutical Co Ltd
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Torii Pharmaceutical Co Ltd
TSE:4551
Accounts Receivables
ÂĄ25.3B
CAGR 3-Years
9%
CAGR 5-Years
0%
CAGR 10-Years
1%
Takeda Pharmaceutical Co Ltd
TSE:4502
Accounts Receivables
ÂĄ700.5B
CAGR 3-Years
-6%
CAGR 5-Years
-2%
CAGR 10-Years
4%
Daiichi Sankyo Co Ltd
TSE:4568
Accounts Receivables
ÂĄ531.8B
CAGR 3-Years
24%
CAGR 5-Years
9%
CAGR 10-Years
7%
Otsuka Holdings Co Ltd
TSE:4578
Accounts Receivables
ÂĄ470.4B
CAGR 3-Years
9%
CAGR 5-Years
6%
CAGR 10-Years
4%
Chugai Pharmaceutical Co Ltd
TSE:4519
Accounts Receivables
ÂĄ239.7B
CAGR 3-Years
-6%
CAGR 5-Years
4%
CAGR 10-Years
6%
Astellas Pharma Inc
TSE:4503
Accounts Receivables
ÂĄ558.3B
CAGR 3-Years
16%
CAGR 5-Years
11%
CAGR 10-Years
5%
No Stocks Found

Torii Pharmaceutical Co Ltd
Glance View

Market Cap
124.7B JPY
Industry
Pharmaceuticals

Torii Pharmaceutical Co., Ltd. engages in the manufacturing and marketing of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 560 full-time employees. The company went IPO on 2013-10-01. The Company’s main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Company’s main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.

Intrinsic Value
3 292.36 JPY
Overvaluation 26%
Intrinsic Value
Price

See Also

What is Torii Pharmaceutical Co Ltd's Accounts Receivables?
Accounts Receivables
25.3B JPY

Based on the financial report for Sep 30, 2024, Torii Pharmaceutical Co Ltd's Accounts Receivables amounts to 25.3B JPY.

What is Torii Pharmaceutical Co Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
1%

Over the last year, the Accounts Receivables growth was -2%. The average annual Accounts Receivables growth rates for Torii Pharmaceutical Co Ltd have been 9% over the past three years , and 1% over the past ten years .

Back to Top